Next, we rescued IRF8 expression (WT, S55A, N87Y, Q392X, D400G, and I424T) in the IRF8 KO A20 and 2PK-3 B cell lymphoma models (Fig. 4B) and used the DO-11.10 CD4 assay to test the impact of IRF8 mutations on antigen presentation/T cell activation (here, no analysis of CD8 OT-I cells was warranted given that IRF8 KO did not affect CD8 activation). Here, CD4 is linked to B-cell non-Hodgkin lymphoma.